WO2012099940A3 - Methods and compositions for treating ocular disease - Google Patents

Methods and compositions for treating ocular disease Download PDF

Info

Publication number
WO2012099940A3
WO2012099940A3 PCT/US2012/021687 US2012021687W WO2012099940A3 WO 2012099940 A3 WO2012099940 A3 WO 2012099940A3 US 2012021687 W US2012021687 W US 2012021687W WO 2012099940 A3 WO2012099940 A3 WO 2012099940A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye
compositions
carotenoid
ocular disease
treating ocular
Prior art date
Application number
PCT/US2012/021687
Other languages
French (fr)
Other versions
WO2012099940A2 (en
Inventor
Paul S. Bernstein
Binxing LI
Original Assignee
University Of Utah Reseach Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Reseach Foundation filed Critical University Of Utah Reseach Foundation
Publication of WO2012099940A2 publication Critical patent/WO2012099940A2/en
Publication of WO2012099940A3 publication Critical patent/WO2012099940A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

This disclosure provides methods and compositions for treating ocular disease. Some embodiments include administering to an eye an expression vector comprising a gene encoding a carotenoid-binding protein operatively linked to a regulatory sequence adapted to direct expression of the carotenoid-binding protein in the retina of an eye. Some embodiments include introducing to an eye an RNA molecule adapted to reduce expression of a carotenoid-metabolizing protein in the retina of the eye.
PCT/US2012/021687 2011-01-18 2012-01-18 Methods and compositions for treating ocular disease WO2012099940A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161461428P 2011-01-18 2011-01-18
US61/461,428 2011-01-18

Publications (2)

Publication Number Publication Date
WO2012099940A2 WO2012099940A2 (en) 2012-07-26
WO2012099940A3 true WO2012099940A3 (en) 2012-10-26

Family

ID=46516341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/021687 WO2012099940A2 (en) 2011-01-18 2012-01-18 Methods and compositions for treating ocular disease

Country Status (1)

Country Link
WO (1) WO2012099940A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020176862A1 (en) * 2019-02-28 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection of neuronal soma and axon by modulating er stress/upr molecules
GB202005641D0 (en) * 2020-04-17 2020-06-03 Ucl Business Plc Gene therapy for bardet-biedl syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402664B2 (en) * 2002-09-03 2008-07-22 Genencor International, Inc. Nucleic acids and expression vectors comprising carotenoid binding peptides
US20090081178A1 (en) * 2002-10-08 2009-03-26 Murray Christopher J Phenolic Binding Peptides
US20100184838A1 (en) * 2007-04-13 2010-07-22 Tufts University Compositions and methods for retinal transduction and photoreceptor specific transgene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402664B2 (en) * 2002-09-03 2008-07-22 Genencor International, Inc. Nucleic acids and expression vectors comprising carotenoid binding peptides
US20090081178A1 (en) * 2002-10-08 2009-03-26 Murray Christopher J Phenolic Binding Peptides
US20100184838A1 (en) * 2007-04-13 2010-07-22 Tufts University Compositions and methods for retinal transduction and photoreceptor specific transgene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, B. ET AL.: "Human ocular carotenoid-binding proteins", PHOTOCHEM PHOTOBIOL SCI., vol. 9, no. 11, November 2010 (2010-11-01), pages 1418 - 1425 *

Also Published As

Publication number Publication date
WO2012099940A2 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
PH12015501352A1 (en) Compositions and methods that utilize a peptide tag that binds to hyaluronan
PH12018500401B1 (en) Antibodies specific for tgf-beta
WO2014022739A3 (en) Modified rnai agents
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
PH12014502713A1 (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
TR201900649T4 (en) Mrna therapy for the treatment of ocular diseases.
EP4371615A3 (en) Treatment of amd using aav sflt-1
WO2012122025A3 (en) Vectors conditionally expressing protein
EA201270018A1 (en) Opsync ligands, compositions and methods of use
WO2011083150A3 (en) Obesity small molecules
UA113627C2 (en) CRYSTAL FORM OF CYCLOSPORIN A, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
EP3653205A3 (en) Oxymethazoline for topical ophthalmic administration and uses thereof
EA201500371A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIPOETHIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF AGENTS
EA201400002A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
UA107836C2 (en) Treatment of alzheimer's disease
MX2014005209A (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent.
WO2014028668A3 (en) Stem cell enhancing therapeutics
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
WO2012154695A3 (en) Treatment of polycystic disease
EA201490012A1 (en) Opsin-binding ligands, compositions and methods of their use
EA201500370A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIOPOETIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF-R AGENTS
GB201110777D0 (en) Methods and uses
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
WO2014161004A3 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12737146

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12737146

Country of ref document: EP

Kind code of ref document: A2